The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.00
Bid: 5.75
Ask: 5.95
Change: -0.525 (-8.24%)
Spread: 0.20 (3.478%)
Open: 6.25
High: 6.25
Low: 6.00
Prev. Close: 6.375
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Positive Developments with Harpin

14 Nov 2018 07:00

RNS Number : 2566H
Plant Health Care PLC
14 November 2018
 

 

 

14 November 2018

PLANT HEALTH CARE plc

 

("Plant Health Care" or the "Company")

 

Positive Developments with Harpin ab in sugarcane in Brazil

 

Plant Health Care®, a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update on the launch of H2Copla (Harpin ab) in sugarcane in Brazil.

 

Highlights:

- H2Copla (Harpin ab) has been applied on some 20,000 hectares (Ha) of sugarcane since 'soft launch' in February 2018

- Average yield increases in excess of 20% are driving strong demand; early adopters plan to switch entirely to H2Copla for the next season

- Grower response to the results has been very positive

- Sales by PHC to Coplacana are expected to reach $0.8m in 2018, pointing to strong growth in 2019

 

As previously announced, Brazil sugarcane, with 10 million Ha planted, is an important target for Plant Health Care. The Company has been developing Harpin ab for use in this crop since 2016. Coplacana, a very large co-operative and the leading distributor of inputs for sugarcane, was appointed as distributor to launch Harpin ab under the brand name H2Copla. Following a 'soft launch' in February 2018, Coplacana has been carrying out extensive demonstration trials of the product; H2Copla has been applied on some 20,000 Ha to date by various growers.

 

Trials conducted on behalf of the Company in 2018 showed that single applications of a low dose (100 g per Ha), significantly increased the yield of sugarcane (10-29%). Moreover, it is possible that the life of the crop may be extended from five to six years, resulting in a material cost reduction for the grower, especially when sugar prices are low. Grower response to the results has been very positive.

 

Furthermore Usina Açucareira Furlan S/A ('Furlan'), a large sugarcane producer located in the state of São Paulo, carried out field trials in 2018, as part of the soft launch by Coplacana, which delivered an average 23% yield increase from H2Copla applicatons. Furlan now plans to use H2Copla on their entire area next season.

 

Gilmar Rorigues de Morais, Agriculture Department Manager at Furlan, said "We are excited about the yield increases from this year's trials and plan to use H2Copla on all of our 20,000 Ha for the 2019 growing season."

 

Chris Richards, Executive Chairman and Interim CEO of Plant Health Care, noted: "Grower reaction to demonstration trials of H2Copla has been very positive. Growers have already treated some 20,000 Ha of sugarcane with the product. The indication that just one customer (Furlan) plans to use H2Copla on 20,000 Ha next year, points to significant revenue growth in 2019. Demand for Harpin ab in Brazil is expected to reach at least $0.8m in 2018."

For further information, please contact:

 

Plant Health Care plc

Chris Richards, Executive Chairman and Interim CEO Tel: +1 919 926 1600

Jeff Tweedy, COO

 

Arden Partners plc - Nomad and BrokerJohn Llewellyn-Lloyd / Dan Gee-Summons Tel: +44 (0) 20 7614 5900

 

IFC Advisory - Financial PR

Graham Herring / Miles Nolan / Zach Cohen Tel: +44 (0) 20 3934 6633

 

 

Company website: www.planthealthcare.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDUOUWRWSAAAAA
Date   Source Headline
16th Jun 20207:00 amRNSPHC398 Approved by US EPA: PHC279 submitted to EPA
9th Jun 20207:00 amRNSGrant of options
2nd Jun 202011:13 amRNSResult of AGM
29th May 20207:00 amRNSHolding(s) in Company
27th May 20207:00 amRNSUpdate on PHC279 2019 Field Trials
6th May 20205:12 pmRNSAnnual Report & Accounts and AGM Notice Published
1st May 20203:21 pmRNSDirector/PDMR Shareholding
24th Apr 20207:00 amRNSResults for the year ended 31 December 2019
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20203:45 pmRNSHolding(s) in Company
19th Mar 20203:09 pmRNSHolding(s) in Company
16th Mar 202011:53 amRNSResults of General Meeting
11th Mar 20207:00 amRNSPHC279 Submitted for Regulatory Approval in Brazil
24th Feb 20209:18 amRNSResults of Placing and Subscription
24th Feb 20207:00 amRNSProposed Placing and Subscription
19th Feb 20207:00 amRNSBlock listing Interim Review
5th Feb 20207:00 amRNSEmploy California Registration
23rd Jan 20207:00 amRNSFirst US patent issues for PREtec peptide products
9th Jan 20207:00 amRNSBrazil Update
20th Dec 20197:00 amRNSHolding(s) in Company
19th Dec 20197:00 amRNSTrading Update
3rd Dec 20196:35 pmRNSHolding(s) in Company
22nd Nov 20192:11 pmRNSHolding(s) in Company
15th Nov 20193:42 pmRNSHolding(s) in Company
15th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSHolding(s) in Company
13th Nov 20194:40 pmRNSHolding(s) in Company
13th Nov 20194:08 pmRNSHolding(s) in Company
13th Nov 20193:59 pmRNSHolding(s) in Company
13th Nov 20193:42 pmRNSHolding(s) in Company
12th Nov 20193:56 pmRNSHolding(s) in Company
6th Nov 201912:57 pmRNSInvestment in Company by Ospraie Ag Science LLC
30th Oct 20197:00 amRNSAppointment of new Board Directors
3rd Oct 20192:50 pmRNSDirector/PDMR Shareholding
30th Sep 20197:00 amRNSInterim Report ended 30 June 2019
9th Sep 20197:00 amRNSPilot production of PREtec peptides
19th Aug 20197:00 amRNSBlock listing Interim Review
15th Aug 20197:00 amRNSProgress with PREtec field trials in Brazil
5th Aug 20195:18 pmRNSHolding(s) in Company
25th Jun 20197:00 amRNSNew Distribution Agreement with Wilbur-Ellis
12th Jun 201911:05 amRNSResult of AGM
30th Apr 20194:19 pmRNSAnnual Report & Accounts and AGM Notice Published
10th Apr 20197:00 amRNSResults for the year ended 31 December 2018
27th Mar 20193:41 pmRNSHolding(s) in Company
28th Feb 20197:00 amRNSNew Technology Update
19th Feb 20197:00 amRNSBlock listing Interim Review
29th Jan 20197:00 amRNSTrading Statement
24th Jan 20195:58 pmRNSHolding(s) in Company
21st Dec 20187:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.